The Pepticom team are thrilled to announce that Dr. Tomi Sawyer, a world leading Key Opinion Leader (KOL) in the field of peptide drug discovery, and a current member of the Pepticom scientific advisory board, has been nominated as the Head of the Pepticom Scientific Advisory Board!
Among his many accolades, Tomi is renowned for the discovery of two FDA-approved drugs, including Scenesse®️ (marketed by Clinuvel) and Iclusig®️ (marketed by Takeda) as well as scientific contribution to the design of macrocyclic peptides, including ALRN-6924 (currently in Phase II clinical trials by Aileron Therapeutics).
Happy to have you onboard Tomi!
